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Open Forum Infectious Diseases
MAJOR ARTICLE
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Background. Patients with recurrent Clostridium difficile infection (rCDI) are more likely to have a hospital readmission and
spend increased time in inpatient settings compared with patients with primary CDI. MODIFY I and II demonstrated that bezlotoxumab significantly reduced rCDI vs placebo. A post hoc within-trial analysis assessed whether bezlotoxumab was associated with a
reduction in cumulative inpatient-days.
Methods. Data were pooled from the MODIFY trials to estimate the cumulative hospitalized days summed over the 84-day
follow-up period. We adjusted inpatient use data from pooled MODIFY I and II for survival and censoring to estimate 84-day cumulative inpatient-days, overall and for subgroups. Treatment effects were obtained using recycled predictions based on trial protocol
and rCDI risk, and 95% confidence intervals were obtained using 1000 bootstrap replicates.
Results. Mean cumulative inpatient-days were greater in the placebo arm (14.1 days) vs the bezlotoxumab arm (12.1 days) in
the overall population. The mean difference between treatment groups was 2.1 days (95% confidence interval, –0.4 to –3.7). This
was consistent in participants with risk factors for rCDI: age ≥65 years, compromised immunity, severe CDI, prior CDI, and ribotype 027/078/244 infection. As the number of risk factors increased, bezlotoxumab resulted in greater reductions in the number
of inpatient-days compared with placebo (difference: –1.2 days, –2.3 days, –2.5 days, and –3.0 days for 0, 1, 2, and ≥3 risk factors,
respectively).
Conclusions. Bezlotoxumab was associated with a reduction in cumulative inpatient-days, suggesting that treatment with bezlotoxumab may substantially reduce rCDI-associated health care resource use.
Trial registrations. MODIFY I (MK-3415A-001, NCT01241552) and II (MK-3415A-002, NCT01513239)
Keywords. CDI burden of disease; Clostridium difficile infection; recurrence; rehospitalization.
Approximately 25% of patients experience recurrent
Clostridium difficile infection (rCDI) after completing initial
therapy with metronidazole or vancomycin [1, 2]. The risk of a
second recurrence increases to approximately 40% [3] with significantly increasing costs for inpatients with rCDI compared
with primary CDI [4]. Factors associated with an increase in
rCDI include age ≥65 years [5], inadequate immune response
[6], severe CDI [7, 8], prior CDI episode(s) [3], and infection
with the B1/NAP1/027 strain [9–12].
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Overall, patients with rCDI experience significantly higher
rates of hospital readmission vs patients without rCDI (85%
vs 41%) [13] and have longer hospital stays (19 days vs 8 days;
P < .001) [13]; more than 40% of index hospitalizations associated with CDI result in discharge to long-term care, followed
by readmission to the hospital within 90 days (all-cause readmissions) [14]. Recurrent episodes of CDI are associated with
excessive costs, and these are attributable to significantly longer
hospital stays, including more days in the intensive care unit in
tertiary care settings, compared with primary episodes of CDI
[4, 15].
The human monoclonal antibody bezlotoxumab is a novel
antitoxin agent that, when given as a single intravenous dose during standard of care antibiotic therapy, reduced rCDI compared
with antibiotic therapy alone (placebo group) over a 12-week
period in 2 independent, phase III, global trials (adjusted difference between groups in rCDI was –10.1% in MODIFY I and
–9.9% in MODIFY II; both P < .001) [16]. Furthermore, in a
post hoc analysis, the reduction in rCDI was greater in participants at high risk for rCDI (adjusted difference between groups
Bezlotoxumab Reduces Inpatient-Days • OFID • 1
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Bezlotoxumab Is Associated With a Reduction in
Cumulative Inpatient-Days: Analysis of the Hospitalization
Data From the MODIFY I and II Clinical Trials

METHODS

MODIFY I (NCT01241552) and II (NCT01513239) were randomized, double-blind, placebo-controlled, multicenter, phase
III trials that were conducted from November 2011 through
May 2015 at 322 sites in 30 countries. The protocols and all
amendments were approved by the institutional review board
or independent ethics committee at each study center. Each
study was conducted in accordance with Good Clinical Practice
Guidelines and the Declaration of Helsinki. Written informed
consent was obtained before study procedures were performed.
Participants

Adults with primary or rCDI receiving oral standard of care antibiotics (metronidazole, vancomycin, or fidaxomicin, chosen by
the treating physician) for 10–14 days were included in the trial.
CDI was defined as diarrhea (≥3 unformed bowel movements
in 24 hours) associated with a positive stool test for toxigenic
C. difficile or its toxins. To monitor for new episodes of diarrhea,
participants recorded daily loose stool counts in a diary through
12 weeks. Participants included in this analysis received either a
single dose of bezlotoxumab 10 mg/kg or placebo (0.9% saline)
during antibiotic treatment. Randomization was stratified by oral
antibiotic treatment for CDI (metronidazole, vancomycin, or fidaxomicin) and hospitalization status (inpatient or outpatient).
Population, End Points, and Statistical Methods

The analysis population was the modified intent-to-treat
(mITT) population (defined as all randomly assigned participants who received study infusion, had a positive stool test for
toxigenic C. difficile or its toxins, and began standard of care
antibiotic therapy before or within 1 day after receiving the
study infusion) in the pooled data set from MODIFY I and
MODIFY II. Subgroups were characterized by known risk factors for CDI recurrence that had been prespecified in the protocols: ≥65 years of age, immunocompromised, severe CDI,
hypervirulent strain (ribotypes 027, 078, or 244), and/or ≥1 episode of CDI in previous 6 months. Additional subgroups were
defined based on the total number of prespecified risk factors:
no risk factors, at least 1 risk factor, only 1 risk factor, only 2
risk factors, and ≥3 risk factors. The primary end point for this
2 • OFID • Basu et al

post hoc analysis was cumulative inpatient-days in any hospital
setting during the 84 days following infusion.
We first modeled the probability of surviving each follow-up
day, after adjusting for censoring using a standard accelerated
failure time model. Then, using the longitudinal data set of up
to 84 observations per person, we estimated the probability of
spending a day in the hospital using a logistic model. The independent variables for this model included sex, race, age, inpatient status, NAP 1 strain, Charlson Severity Score, history of
CDI, being immunocompromised, and region (US vs ex-US).
Lin’s (2000) method was applied, where the day-specific probability of spending a day in the hospital among those noncensored was multiplied by the estimated day-specific probability
of survival and then summed over all 84 days to obtain the estimate of cumulative inpatient-days, adjusted for censoring [18].
Censoring occurred, as cost data were not available for patients
who discontinued from the trial. Lin’s method was adopted to
account for censoring by appropriately weighting the uncensored costs with inverse probability of inclusion (survival
probability). Lin’s method is an improvement over traditional
methods such as analyzing censored cost data by excluding subjects, as these methods do not utilize complete information by
ignoring censored subjects and may result in bias. Treatment
effects were obtained using recycled predictions by turning on
and off the treatment indicator for all participants in our overall sample and for subgroups identified based on trial protocol
and risk of rCDI. P values and 95% confidence intervals were
obtained using 1000 clustered bootstrap replicates. Statistical
analyses were conducted using Stata, version 11.
RESULTS
Study Population

There were 1554 participants (bezlotoxumab group: 781; placebo group: 773) included in the mITT population across both
studies. Demographic and clinical characteristics were balanced
between the study groups (Table 1) and have been previously
reported [16]. The median age (range) was 66 (18–100) years,
86% were white, and 56% were women.
Treatment with bezlotoxumab was associated with a reduction in cumulative inpatient-days compared with placebo
(Figure 1) during 84 days of follow-up. In the overall population, participants treated with bezlotoxumab spent an average of
2.1 fewer days (95% CI, –0.4 to –3.7) in the hospital compared
with participants who received placebo. Similarly, in all subgroups assessed, including those with no risk factors and those
with factors associated with rCDI, bezlotoxumab treatment was
associated with a reduction in cumulative inpatient-days compared with those receiving placebo during the 84-day follow-up
period. The greatest reduction in inpatient-days was observed
in participants with severe CDI at study entry (–3.5 days)
(Figure 1). As the number of risk factors for rCDI increased,
the reduction in the number of inpatient-days also increased
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in rCDI was –15.9% (95% confidence interval [CI], –21.6
to –10.2) in participants with ≥1 risk factor for rCDI) [17].
Bezlotoxumab neutralizes C. difficile toxin B. Neutralization of
toxin B prevents new symptoms of CDI during the period when
there is a high risk of rCDI, thereby preventing clinical relapse.
Bezlotoxumab’s demonstrated efficacy in reducing rCDI over
a 12-week period suggests that health care resource utilization
and associated costs may also be reduced in patients receiving
bezlotoxumab. This post hoc analysis was conducted to assess
whether bezlotoxumab reduced the number of days participants spent in the hospital (cumulative inpatient-days) over a
12-week period compared with placebo.

Table 1.

Participant Demographic and Clinical Characteristics
Bezlotoxumab
(n = 781)

Placebo
(n = 773)

Inpatient

530 (67.9)

520 (67.3)

Female sex

442 (56.6)

449 (58.1)

Age ≥65 y

390 (49.9)

405 (52.4)

Characteristic

SOC antibiotic
365 (46.7)

353 (45.7)

370 (47.4)

372 (48.1)

Fidaxomicin

30 (3.8)

30 (3.9)

216 (27.7)

219 (28.3)

≥1 episode of CDI in previous 6 mo
≥2 previous CDI episodes ever

100 (12.8)

126 (16.3)

Severe CDIa

122 (15.6)

125 (16.2)

Immunocompromisedb

178 (22.8)

153 (19.8)

Other antibiotic use during SOC therapyc

292 (37.4)

317 (41.0)

Other antibiotic use after SOC therapyc

273 (35.0)

275 (35.6)

Renal impairmentd

123 (15.7)

110 (14.2)

49 (6.3)

44 (5.7)

Participants with positive culture

490 (62.7)

486 (62.9)

027, 078, or 244 strainf

102 (20.8)

115 (23.7)

89 (18.2)

100 (20.6)

Hepatic impairmente
PCR ribotype

027 strainf

Abbreviations: CDI, Clostridium difficile infection; PCR, polymerase chain reaction; SOC,
standard of care.
a
Severe infection was defined as a Zar score of 2 or higher. The Zar score ranges from 1
to 8 and is based on the following factors: age greater than 60 years (1 point), body temperature higher than 38.3°C (100°F) (1 point), albumin level lower than 2.5 g per deciliter
(1 point), peripheral white cell count higher than 15 000 per cubic millimeter within 48
hours (1 point), endoscopic evidence of pseudomembranous colitis (2 points), and treatment in an intensive care unit (2 points).
b
The determination of whether a participant was immunocompromised was made on the
basis of medical history or use of immunosuppressive therapy.
c
Included are systemic antibiotics other than the standard of care antibiotic that was
given to treat C. difficile infection.
d
Renal impairment was defined as a serum creatinine level of 1.5 mg per deciliter
(133 μmol per liter) or higher.
e
Hepatic impairment was defined as having 2 or more of the following: an albumin level
of 3.1 g per deciliter or lower, an alanine aminotransferase level at least 2 times the upper
limit of the normal range, a total bilirubin level at least 1.3 times the upper limit of the normal range, or mild, moderate, or severe liver disease (as reported on the Charlson Index).
f
The denominators used to calculate percentages are the numbers of participants who
had a positive culture.

with bezlotoxumab vs placebo (difference: –1.2 days in participants with no risk factors, –2.3 days in those with 1 risk factor,
–2.5 days in those with 2 risk factors, and –3.0 days in those
with ≥3 risk factors) (Figure 1).
DISCUSSION

We used pooled data from 2 placebo-controlled, multicenter
clinical trials to assess the impact of bezlotoxumab treatment
on cumulative inpatient-days from any cause over 84 days of
follow-up. Our post hoc analysis demonstrated that bezlotoxumab treatment was associated with reduced cumulative inpatient stay of 2.1 days in the overall trial population, with even
greater reductions observed in participants with 1 or more risk
factors associated with recurrence of CDI. The inpatient subgroup, presumably a sicker subgroup, is also noted to have a
larger reduction in cumulative inpatient-days. As the number of
risk factors increased, participants treated with bezlotoxumab
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Metronidazole
Vancomycin

experienced incrementally greater reductions in the cumulative
inpatient-days compared with placebo.
A 2014 model-based estimate of the economic burden of
CDI in the United States was substantial at $5.4 billion, mainly
attributable to hospitalization [19]. A US MarketScan database study with coverage of more than 45 million members
estimated the 6-month health care costs attributable to rCDI
at $10 580 (95% CI, $8849 to $12 446), with cumulative hospitalized days attributable to rCDI of 1.95 (95% CI, 1.48 to
2.43) [20], comparable to the study by Dubberke et al. (2014) in
which the estimated attributable cost of rCDI was $11 631 (95%
CI, $8937 to $14 588) [4]. With the incidence of CDI-associated
hospital readmissions rising [13], it is important to find innovative treatment options to reduce rCDI and rCDI-associated
hospital admissions. The results of the current analysis are consistent with a related post hoc analysis of the MODIFY trials in
the subgroup of participants who were hospitalized at the time
of randomization, demonstrating that bezlotoxumab-treated
inpatients experienced fewer CDI-associated readmissions during the 30 days after discharge compared with placebo-treated
inpatients [21].
The MODIFY trials, which included a prespecified subgroup analysis of participants with risk factors associated with
an increase in rCDI or CDI-related adverse outcomes, afforded
an opportunity to examine differences in all-cause cumulative
inpatient-days in an unbiased manner. In the post hoc analysis at hand, we observed that as the number of risk factors
increased, the number of cumulative inpatient-days in the placebo arm also increased, suggesting that the presence of multiple risk factors is associated with an increase in number of days
spent in an inpatient facility. This is consistent with another
post hoc analysis of the MODIFY trials that demonstrated
that the proportion of participants experiencing rCDI in the
placebo arm increased as the number of risk factors increased
[17]. Regardless of the number of risk factors, treatment with
bezlotoxumab was associated with a reduction in cumulative
inpatient-days during the 84-day follow-up period compared
with placebo. Taken together, bezlotoxumab treatment is consistent with an overall reduction in recurrence, readmissions,
and cumulative inpatient-days, suggesting that its use may be an
effective treatment for reducing the overall health care resource
use associated with CDI.
A cost-effectiveness model showed that bezlotoxumab is
cost-effective in the prevention of recurrent CDI compared
with placebo among participants receiving standard of care
antibiotics for treatment of CDI [22]. With the average cost
for 1 inpatient-day in the United States estimated at $2013 in
2015 [23], and an estimated reduction in hospital-days of 2.0
to 3.0 days, depending upon the number of risk factors, the
evidence suggests that treatment with bezlotoxumab may substantially reduce direct treatment costs associated with rCDI.
A within-trial health-economic evaluation is needed to further

Bezlotoxumab
Days
N
Overall patient population
a

Inpatient population

Placebo
Days
N

Absolute
Difference

12.1

781

14.1

773

–2.1

17.7

520

20.3

530

–2.9

14.3

390

16.7

405

–2.4

Difference (95% CI)
Bezlo - Placebo

Prespecified risk factors

historyb

11.3

216

13.2

219

–1.9

Immunocompromisedc

16.4

178

19.2

153

–2.7

Severe CDId

21.8

122

25.3

125

–3.5

Ribotype 027/078/244

15.3

102

17.9

115

–2.6

No risk factors

6.9

189

8.1

190

–1.2

≥1 risk factor

13.8

592

16.1

583

–2.3

1 risk factor

11.5

283

13.6

274

–2.0

2 risk factors

14.5

220

17.0

208

–2.5

≥3 risk factors

18.6

89

21.5

101

–3.0

CDI

Aggregate risk factors

–7

Favors bezlo

–6

–5

–4

–3

–2

–1

Favors placebo

0

1

Figure 1. Estimated mean cumulative inpatient-days summed over 84 days in the modified intent-to-treat population. aInpatients at the time of study randomization. bHistory of Clostridium difficile infection recurrence within the previous 6 months. cDefined on the basis of a subject’s medical history or use of immunosuppressive therapy. dZar
score ≥2 based on the following: (1) age >60 years (1 point); (2) body temperature >38.3°C (>100°F; 1 point); (3) albumin level <2.5 mg/dL (1 point); (4) peripheral white blood
cell count >15 000 cells/mm3 within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care unit (2 points).
Abbreviations: CDI, Clostridium difficile infection; CI, confidence interval.

assess the value of bezlotoxumab, as bezlotoxumab could potentially be cost-saving among patients with ≥1 risk factor. Further,
this work is consistent with the labeled claim for bezlotoxumab
and data demonstrating that bezlotoxumab has a higher impact
where it matters—among patients who are at risk for rCDI [17].
There are some limitations of this post hoc analysis. First, it was
not powered for hypothesis testing. In addition, we did not assess
CDI-associated hospital-days; rather we assessed days spent in the
hospital for any reason. Therefore, we may be overestimating the
specific CDI burden, although the amount of overestimation should
be equivalent for both the bezlotoxumab and placebo groups. One
population-based, retrospective cohort study among adult inpatients in 29 hospitals found that the risk of readmission for CDI
was higher in the first 12 weeks after discharge; after 12 weeks, the
risk of readmission dropped to a stable, low level, suggesting that
we captured the majority of CDI-associated readmissions during
the 84-day follow-up period [24]. Of note, the MODIFY trials may
have enrolled a healthier population compared with real-world
patients with CDI (despite including a broad population with few
exclusion criteria), potentially reducing the estimated number of
non-CDI-related hospital-days in this analysis. Another limitation
was that we only counted acute care hospitalization–days and did
not count days in a long-term care facility or rehabilitation center.
4 • OFID • Basu et al

As with any clinical trial, there was early loss to follow-up of some
patients, which could lead to underestimation of average hospital-days. Our methods directly addressed this censoring using a
missing-at-random assumption.
In conclusion, the analysis presented here suggests that bezlotoxumab treatment may result in reduced health care resource
utilization, especially among patients at high risk for CDI
recurrence.
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